Bicisate description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Bicisate

AnazaoHealth Corporation

Bicisate (ECD) (for the preparation of Tc99m Bicisate injection)




FULL PRESCRIBING INFORMATION

Dear Medical Professional,

Per your order, we have compounded ECD as a sterile freeze-dried preparation. The characteristics of this preparation are:

AnazaoHealth supplies ECD as a compounded kit for preparing Tc99m ECD. Each Reaction vial contains 1.35 mg of ECD, 0.54 edetate disodium, 36mg mannitol and 0.125 mg stannous chloride dehydrate. The vial is back filled with inert gas and may contain a partial vacuum.

Each ECD buffer vial contains a total volume of 1 mL that includes 6.15 mg sodium phosphate dibasic  and 0.69 mg sodium phosphate monobasic

Tc99m Bicisate forms a stable, lipophilic complex that crosses intact cell membranes and blood brain barrier by passive diffusion. The amount of tc99m bicisate is stable in the brain until about 6 hours

Tc99m bicisate is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed

The physical half-life for Technetium is 6.02 hours

There are no known contraindications for this preparation.

The recommended dose  for a 70 kg patient is 10-30 mCi

For best results, use tc99m from a generator eluted within 24 hours.  The eluate should be used within 2 hours of elution.

  Reconstitution Instructions:

  • Snap off the plastic lid and place in appropriate lead shielding. Wipe the septum with 70% isopropyl alcohol and allow it to dry.
  • Using a 10 mL syringe, draw up 100 mCi of tc99m (in approximately 2 mL) and inject into the ECD Buffer, being sure to withdraw an equal amount of gas from the vial to neutralize pressure.
  • With a sterile syringe, inject 3 mL of 0.9% sodium chloride into the reaction vial to dissolve the contents. Remove an equal volume of air to maintain pressure within the vial. Shake the contents of the vial for a few seconds.
  • With another sterile syringe, immediately (within 30 seconds) withdraw  1 mL out of the reaction vial and inject it into the buffer vial. Discard the reaction vial
  • Swirl the contents of the buffer vial for a few seconds and allow this mixture to stand for 30 minutes at room temperature.
  • Examine the vial contents for particulates and discoloration prior to patient administration. It should be clear of any particulates.

It is recommended that the kit be stored refrigerated until use; at such time the product should be aseptically withdrawn

This kit should be stored in the refrigerator prior to reconstitution and the reaction vial protected from light.

Figure 1

Bicisate

Bicisate

Bicisate INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:51808-217
Route of Administration INTRAVENOUS DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
BICISATE BICISATE 1.35 mg

Inactive Ingredients

Ingredient Name Strength
EDETATE DISODIUM
mannitol
STANNOUS CHLORIDE

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:51808-217-01 1 in 1 KIT

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
2012-05-23


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.